IDEXX Laboratories (IDXX) is at an interesting juncture. The market seems divided about its prospects. Its earnings are expected to grow yet significant insiders have sold stock. Some are betting on a big move in the stock. Options traders are likely confident about its fundamentals, even as a question mark hangs over its latest stock performance. Predictably, the firm's financial prospects look strong to some, and its debt is predicted to be manageable. While its share price has been decent, it trails its five-year earnings growth. Investors evidently believe the company is worth watching. However, earnings growth is not keeping pace with shareholder returns. Institutional shareholding is high, but some investment firms are reducing their positions. Its Q3 and Q2 earnings brought misses and downward revisions for 2024. This was because of lower US client visit and a robust dollar that affected revenue creation adversely. Guidance was tightened as vet visits declined. Despite all these, it is seen as a quality stock with strong returns on capital. Nonetheless, the stock has underperformed against competitors. Earnings missed by $0.45 and revenue fell short of estimates, leading to a downgrade. Finally, it seems to continue to draw interest from investors due to its consistent solidity and growth.
Idexx Laboratories IDXX News Analytics from Tue, 29 Aug 2023 07:00:00 GMT to Sat, 26 Oct 2024 07:42:45 GMT -
Rating 2
- Innovation 3
- Information 5
- Rumor -7
